Infectologia
Vigilância global da OMS sobre resistência antimicrobiana a Neisseria gonorrhoeae 2017-18 – Em muitos países, a resistência ao ciprofloxacino foi excessivamente alta e a resistência à ceftriaxona e à cefixima continuou surgindo.
27 Set, 2021 | 12:29h[Preprint] Terceira dose da vacina da Sinopharm com SARS-CoV-2 inativado induz robustas respostas de células B e T.
27 Set, 2021 | 12:13hComentários:
Sinopharm’s COVID booster reverses antibody decline, enhances cell-based responses – study – Reuters
Estudo randomizado de fase 1/2 | Segurança e imunogenicidade de vacina inativada contra COVID-19 (BBIBP-CorV) em crianças e adolescentes de 3 a 17 anos de idade.
27 Set, 2021 | 12:11hConteúdo relacionado: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.
Revisão sistemática | Características clínicas da síndrome inflamatória multissistêmica em adultos.
27 Set, 2021 | 12:08h
Comentário no Twitter
Multisystem inflammatory syndrome has been reported in adults worldwide but may be hard to distinguish from acute biphasic #COVID19 and postacute sequelae of COVID-19. More research is needed to understand this emerging clinical entity. https://t.co/OnerzsZKVB
— JAMA Network Open (@JAMANetworkOpen) September 22, 2021
“Não é um jogo de soma zero”: compartilhar vacinas é do interesse de todos os países.
27 Set, 2021 | 12:06h‘Not a zero-sum game’: Sharing vaccines is in countries’ best interests – YaleNews
Artigo original: National interest may require distributing COVID-19 vaccines to other countries – Scientific Reports
Comentário no Twitter
"when US has reached the threshold for domestic herd immunity, it would be optimal to donate doses to other countries, as this would allow for a sharp reduction in the inflow of infected individuals from abroad"
– Modeling by @SaadOmer3, @amynmalik & co https://t.co/NFfp39tde6— Ahmed Mushfiq Mobarak (@mushfiq_econ) September 16, 2021
A lição da ivermectina: metanálises baseadas somente no resumo dos dados são inerentemente não confiáveis.
27 Set, 2021 | 12:04h
Comentário no Twitter
Flaws in ivermectin data suggest that COVID-19 meta-analyses need rethinking
Correspondence from Jack Lawrence @GidMK @K_Sheldrick and colleagues https://t.co/lUqXX9DQjO pic.twitter.com/Oh848X1VGv
— Nature Medicine (@NatureMedicine) September 22, 2021
[Comunicado de imprensa – ainda não publicado] J&J afirma que dose de reforço depois de 2 meses propiciou 75% de proteção contra COVID-19 moderada a grave globalmente, sendo 94% desses casos nos EUA.
27 Set, 2021 | 11:39hComunicado de imprensa: Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
Comentários:
Johnson & Johnson says additional dose boosts Covid vaccine efficacy – STAT
J&J booster 94% effective against severe COVID, company says – CIDRAP
Two dose version of Johnson & Johnson shot 94% effective against Covid-19, study finds – CNN
Comentários no Twitter
(fio – clique para saber mais)
📍BREAKING—At last—new data on 2-doses of Johnson & Johnson's #vaccine (doses 56 days apart) is 94% effective against symptomatic #COVID19, thus comparable to Moderna/Pfizer. And 100% effective against severe COVID. Booster for 1 dose works well too. 🧵https://t.co/3nPkodOjuG pic.twitter.com/DizjWt9NYX
— Eric Feigl-Ding (@DrEricDing) September 21, 2021
(fio – clique para saber mais)
First press released results out for the double-dose J&J vax trial, ENSEMBLE 2. With 2 months between doses, efficacy against moderate to severe/critical increased – didn't provide overall efficacy data though. Adverse reactions similar to 1st dose …1/n https://t.co/BmBVtLvEaW
— Hilda Bastian, PhD (@hildabast) September 21, 2021
Interpretação dos resultados dos testes de SARS-CoV-2.
27 Set, 2021 | 11:37hInterpreting SARS-CoV-2 Test Results – JAMA
Perspectiva | Desculpe, mas uma infecção por coronavírus pode não ser o suficiente para proteger você – “Qualquer um que prefira ter COVID-19 do que se vacinar está fazendo uma aposta dupla: que a imunidade se mantenha, e os sintomas, não.”
27 Set, 2021 | 11:35hSorry, a Coronavirus Infection Might Not Be Enough to Protect You – The Atlantic
[Preprint] Vírus parecidos com SARS podem passar de animais para pessoas centenas de milhares de vezes ao ano.
27 Set, 2021 | 11:34hSARS-like viruses may jump from animals to people hundreds of thousands of times a year – Science
Estudo original: A strategy to assess spillover risk of bat SARS-related coronaviruses in Southeast Asia – medRxiv
Conteúdos relacionados:
Did the coronavirus jump from animals to people twice? – Nature
The Origins of SARS-CoV-2: A Critical Review.
Fauci says natural origins theory of coronavirus is still the most likely.